Oppenheimer Reiterates Outperform on ESSA Pharma, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Mark Breidenbach has reiterated his 'Outperform' rating on ESSA Pharma (NASDAQ:EPIX) and maintained a price target of $17.
August 09, 2023 | 1:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer's reiteration of an 'Outperform' rating and a maintained price target of $17 could positively impact ESSA Pharma's stock in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. In this case, Oppenheimer's reiteration of an 'Outperform' rating and a maintained price target of $17 for ESSA Pharma indicates a positive outlook for the company, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100